137 related articles for article (PubMed ID: 30882255)
1. Safety profile of iron polymaltose infusions.
Lee AYS; Leung SHP
Hosp Pract (1995); 2019 Apr; 47(2):96-98. PubMed ID: 30882255
[TBL] [Abstract][Full Text] [Related]
2. Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia.
Gilmartin CE; Hoang T; Cutts BA; Leung L
Int J Gynaecol Obstet; 2018 Jun; 141(3):315-320. PubMed ID: 29498039
[TBL] [Abstract][Full Text] [Related]
3. A rapid infusion protocol is safe for total dose iron polymaltose: time for change.
Garg M; Morrison G; Friedman A; Lau A; Lau D; Gibson PR
Intern Med J; 2011 Jul; 41(7):548-54. PubMed ID: 21040319
[TBL] [Abstract][Full Text] [Related]
4. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
[TBL] [Abstract][Full Text] [Related]
5. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
6. A budget impact analysis of iron polymaltose and ferric carboxymaltose infusions.
Lim CK; Connolly M; Mirkazemi C
Int J Clin Pharm; 2022 Feb; 44(1):110-117. PubMed ID: 34498215
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
8. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR
Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory bowel disease and anemia: intravenous iron treatment.
Kangaspunta M; Haapamäki J; Färkkilä M; Arkkila P
Scand J Gastroenterol; 2018 Apr; 53(4):430-434. PubMed ID: 29468908
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Bailie GR; Mason NA; Valaoras TG
Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
[TBL] [Abstract][Full Text] [Related]
11. A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia.
Montandon SV; Fajt ML; Petrov AA
Curr Drug Saf; 2016; 11(2):145-8. PubMed ID: 26647917
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron among cystic fibrosis patients.
Hoo ZH; Wildman MJ
J Cyst Fibros; 2012 Dec; 11(6):560-2. PubMed ID: 22717534
[No Abstract] [Full Text] [Related]
13. Skin staining following intravenous iron infusion.
Crowley CM; McMahon G; Desmond J; Imcha M
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31175113
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
[No Abstract] [Full Text] [Related]
15. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
[TBL] [Abstract][Full Text] [Related]
16. [Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
Barea Mendoza JA; Gredilla Zubiría I; González Olmedo J; Mateo Alvarez S
Med Clin (Barc); 2014 Sep; 143(6):284-5. PubMed ID: 24461741
[No Abstract] [Full Text] [Related]
17. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron.
Powers JM; Shamoun M; McCavit TL; Adix L; Buchanan GR
J Pediatr; 2017 Jan; 180():212-216. PubMed ID: 27776750
[TBL] [Abstract][Full Text] [Related]
19. Safety of iron polymaltose given as a total dose iron infusion.
Newnham E; Ahmad I; Thornton A; Gibson PR
Intern Med J; 2006 Oct; 36(10):672-4. PubMed ID: 16958647
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
[No Abstract] [Full Text] [Related]
[Next] [New Search]
